Firstsource tanks 16% in 2 days after Q1 show; brokerages mixed on outlook

Firstsource Solutions shares fell more than 16% over two sessions after its Q1FY27 results. Net profit declined 2% to ₹165.92 crore, while revenue rose 23.9% YoY to ₹2,751.75 crore. Nomura kept a Buy rating, raised target to ₹310, and revised FY27-FY28 EPS estimates. Emkay raised its target to ₹270 but downgraded to Reduce.

Original reporting
Published Aug 10, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 12:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Firstsource tanks 16% in 2 days after Q1 show; brokerages mixed on outlook — source image
Decision brief

The 30-second read

$FSOLBearishMed
01

Why it matters

Net profit declined slightly while revenue grew strongly YoY; brokerages differed on outlook, with Nomura keeping Buy and raising target, while Emkay cut to Reduce citing limited near-term upside after recent returns.

02

Market read

A fresh earnings print with guidance confirmation and a vertical contract termination is being interpreted as insufficient to justify the stock’s recent run, driving a rapid de-rating.

03

What to watch

The article notes Healthcare contract termination due to client leadership change; traders may be underweighting how quickly new wins offset churn, and overemphasizing short-term EPS estimate revisions versus guidance durability.

Relevance 7/10Novelty 6/10Timing: post-Q1FY27 release, during the following two trading sessions

Background

Firstsource Solutions reported Q1FY27 (Apr-Jun 2026) results, then the stock sold off sharply over the next two sessions.

Company-level read

Ticker impact

$FSOLBearishMedium confidence
Context

Firstsource Solutions shares fell over 16% in two sessions after its Q1FY27 results, with net profit down 2% and revenue up 23.9% YoY.

Expected impact

Bearish near term, with volatility likely to persist until investors digest the Healthcare contract termination and FY27 constant-currency growth guidance.

Evidence & confidence

The article ties the selloff to the Q1FY27 release and highlights a contract termination in Healthcare, while only partially offsetting it with deal wins and retained FY27 CC growth guidance; brokerages adjust EPS estimates and targets but differ on rating changes.

Market effects

Signals investor sensitivity to BFS/Telecom and Media growth versus client churn in Healthcare for IT services/operations outsourcing peers.

May weigh on India mid-cap IT services sentiment given the large single-name drawdown tied to earnings.

Limited direct global read-through, but Europe and constant-currency growth commentary could influence cross-region IT services positioning.

Counterpoint

The company retained FY27 constant-currency revenue growth guidance (10-13%) and added multiple large deals and new logos, suggesting the selloff may over-discount execution noise from one vertical.

Key entities

  • Firstsource Solutions Ltd.

    Subject of the article; shares dropped after Q1FY27 results, with revenue up YoY and net profit down slightly.

  • Nomura

    Maintained positive growth view, kept Buy, raised target to ₹310, and revised FY27-FY28 EPS estimates up 2-5%.

  • Emkay

    Raised target to ₹270 but downgraded to Reduce, citing limited near-term upside after strong recent returns.

Related articles

$BYRNMed

Byrna Technologies Reports Fiscal Third Quarter 2026 Results

Byrna Technologies Inc. (BYRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Byrna Technologies Reports Fiscal Third Quarter 2026 Results ANDOVER, Mass., October 8, 2026 - Byrna Technologies Inc. ( “ Byrna ” or the “ Company ” ) (Nasdaq: BYRN) , a personal defense technology company specializing in the development, manufacture, and sale of in

$NGHighAI 8/10

NOVAGOLD Files THIRD Quarter 2026 Report UNLOCKING DONLIN GOLD’S full POTENTIAL and ADVANCING THE PATH TO DEVELOPMENT

NOVAGOLD RESOURCES INC (NG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE NOVAGOLD Files THIRD Quarter 2026 Report UNLOCKING DONLIN GOLD’S full POTENTIAL and ADVANCING THE PATH TO DEVELOPMENT Donlin Gold Transaction announced: NOVAGOLD and Paulson Advisers LLC and its affiliates entered into a series of definitive agreements o

$ACNMed

What could drive Accenture stock higher at upcoming Investor Day

Accenture (ACN) prepares for its Investor Day on Oct 14, 2026, with stock at $197.11, down 22.27% YOY but up 43.33% in 3 months. Management's FY2027 guidance expects 3-6% revenue growth. Recent quarterly revenue was $18.70B, beating estimates, with AI-related bookings and revenue showing significant growth. Technical indicators are constructive but not overbought. Investors await evidence of AI demand, margin expansion, and raised expectations.

$MRKMed

Guggenheim reiterates Merck stock rating ahead of Q3 earnings

Guggenheim maintained a Buy rating and $170 price target for Merck (NYSE:MRK) ahead of Q3 2026 earnings. The firm adjusted estimates, lowering Q3 sales to $17.44B and EPS to $2.08, citing R&D charges. Full-year estimates were also reduced. Merck's earnings call may focus on pipeline progress and recent data releases. The company faces a patent infringement ruling in Europe and has entered a licensing agreement for an oral KRASG12D inhibitor.

$HYPRMed

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to…

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million Preliminary Revenue Represents 53% Sequential Quarterly Growth; Company Reaffirms 2026 Financial Gu